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Abstract
Nicotinamide N-methyltransferase (Nnmt) methylates nicotinamide, a form of vitamin B3, to 
produce N1-methylnicotinamide (MNAM). Nnmt is an emerging metabolic regulator in 
adipocytes but its role in the liver, a tissue with the strongest Nnmt expression, is not known. In 
spite of its overall high expression, here we find that hepatic expression of Nnmt is highly variable 
and correlates with multiple metabolic parameters in mice and in humans. Further, we find that 
suppression of hepatic Nnmt expression in vivo alters glucose and cholesterol metabolism and that 
the metabolic effects of Nnmt in the liver are mediated by its product MNAM. Supplementation of 
high fat diet with MNAM decreases serum and liver cholesterol and liver triglycerides levels in 
mice. Mechanistically, increasing Nnmt expression or MNAM levels stabilizes sirtuin 1 protein, 
an effect, which is required for their metabolic benefits. In summary, we describe a novel 
regulatory pathway for vitamin B3 that could provide a new opportunity for metabolic disease 
therapy.
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Introduction
NAD+ acts as a redox cofactor for more than 200 enzymatic reactions and also serves as a 
co-substrate for the sirtuins, a family of NAD+-dependent deacetylases1–3. Sirtuin 1 (Sirt1), 
the most studied member of the family, has emerged as an important regulator of nutrient 
metabolism. Sirt1 regulates gluconeogenesis through deacetylation of the peroxisome 
proliferator-activated receptor gamma coactivator 1 alpha (Pgc1α), forkhead box O 1 
(FoxO1) and CREB-regulated transcription coactivator 2 (Crtc2), among other factors4–9. 
Sirt1 also suppresses lipogenesis and cholesterol synthesis partly through direct 
deacetylation and inhibition of the master regulators of lipid homeostasis, sterol regulatory 
element binding proteins 1 and 2 (Srebp-1 and −2)10–12. Absence of Sirt1 in the liver 
accelerates the metabolic disturbances of HFD13–15. Conversely, increased Sirt1 activity 
generally confers a metabolically beneficial profile. Transgenic overexpression of Sirt1 or 
increased availability of the Sirt1 substrate, NAD+, ameliorates many of the metabolic 
consequences of diet-induced obesity (DIO) in rodents, such as glucose intolerance, 
cholesterol and fat deposition in the liver, endoplasmic reticulum stress and inflammation 
although adverse effects were also reported16–21. The activity of Sirt1 itself is regulated 
through multiple mechanisms, which include interaction with other proteins and 
posttranslational modifications, both areas of current research22–24. In addition, Sirt1 is 
regulated by the availability of its substrate, NAD+ and may act as a sensor for metabolic 
adaptation to nutritional states. Thus enzymes in NAD+ metabolic pathways may regulate 
metabolism through Sirt125,26. Nnmt is one such enzyme, shown recently to regulate 
adipose tissue energy expenditure partly through global changes in histone methylation and 
increased NAD+ content27. Nnmt methylates nicotinamide (NAM) to MNAM using the 
universal methyl donor S-Adenosyl methionine (SAM) and producing S-adenosyl 
homocysteine (SAH)28–30. MNAM is further oxidized by aldehyde oxidase in the liver to 
two related compounds, 1-methyl-2-pyridone-5-carboxamide and 1-methyl-4-pyridone-3-
carboxamide and all three are excreted in the urine31. Liver is the tissue with the strongest 
Nnmt expression but its role in this tissue is not well understood. In this study we examined 
the role of Nnmt in the liver and demonstrate that Nnmt regulates glucose, lipid and 
cholesterol metabolism by stabilizing Sirt1.
Results
Nnmt expression correlates with metabolic parameters
It has been recently shown that adipose tissue Nnmt expression is increased in mouse 
models of obesity27. For this reason, we examined the regulation of liver Nnmt expression 
by diets and in metabolic disease models. Nnmt expression was higher in the livers of db/db 
mice compared with controls as previously shown27 (Supplementary Fig. 1a). Nnmt 
expression was lower in the livers of ketogenic diet-fed mice (KD) and higher in the livers 
of calorically restricted mice (CR) compared with chow-fed mice. High-fat diet (HFD) 
feeding did not change liver Nnmt (Supplementary Fig. 1b). Consistent with that, MNAM 
content of the liver was not changed by HFD compared with chow (chow 2.88 ± 0.44 vs 
HFD 3.19 ± 0.35 pmol/mg wet weight, n = 8/group, data are mean ± s.e.m). Fasting and re-
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feeding experiments had no effect on liver Nnmt expression in C57BL6/J mice 
(Supplementary Fig. 1c).
Liver Nnmt expression varies widely (∼100-fold) among mouse inbred strains 
(Supplementary Fig. 2). We took advantage of this property and correlated liver Nnmt 
expression with metabolic phenotypes deposited in the Hybrid Mouse Diversity Panel 
(HMDP) database, which aims at finding novel genetic variation influencing metabolic 
diseases32. Liver Nnmt expression correlates inversely with high-density lipoprotein (HDL), 
total cholesterol, triglycerides (TGs), free fatty acids and other parameters (Supplementary 
Table 1). This correlation prompted us to examine the role of Nnmt in metabolic 
homeostasis.
Nnmt regulates glucose and cholesterol metabolism
To establish a causal role for Nnmt regulating some of these metabolic parameters we 
manipulated Nnmt expression through adenoviral knockdown and overexpression in mouse 
primary hepatocytes and in vivo. We initially tested the role of Nnmt in gluconeogenesis, as 
this was the first reported metabolic pathway regulated by Sirt14. Primary hepatocytes with 
Nnmt knockdown (Fig. 1a) had significantly lower hepatocyte glucose output (50%) and 
significantly lower expression of both glucose-6-phosphatase catalytic (G6pc) (20%) and 
phosphoenolpyruvate carboxykinase 1 cytosolic (Pck1) (40%) compared with control 
hepatocytes (Fig. 1b). In contrast, primary hepatocytes with Nnmt overexpression (Fig. 1c) 
had significantly higher glucose output (1.4-fold), 3-fold higher expression of G6pc and 4-
fold higher expression of Pck1 compared with control hepatocytes (Fig. 1d). These data 
indicate that Nnmt is a positive regulator of gluconeogenesis in primary hepatocytes.
To test the role of Nnmt in vivo, we knocked down Nnmt in the liver of C57BL6/J mice 
using adenovirus. Nnmt knockdown mice had significantly lower overnight fasting glucose 
levels compared with control mice, whereas fasting insulin did not change (Fig. 1e). 
Pyruvate conversion to glucose was significantly lower in mice with Nnmt knockdown 
(50%), suggesting reduced gluconeogenesis in vivo (Fig. 1f). Expression of G6pc and 
fructose bisphosphatase 1 (Fbp1) was lower in the livers from Nnmt knockdown mice 
compared with control mice, while Pck1 and pyruvate carboxylase (Pcx) expression was not 
changed (Fig. 1g). Serum and hepatic TGs levels did not differ (data not shown) but serum 
and liver cholesterol levels were significantly higher in ad libitum-fed Nnmt knockdown 
mice compared with controls (Fig. 1h). Expression of Srebf2, the first two genes in the 
cholesterol synthesis pathway Hmgcr and Hmgcs1, and expression of several receptors and 
transporters in the cholesterol pathway, Abcg5, Scarb1, and Abcb11 were also higher (1.3–2 
fold) in the livers of Nnmt knockdown mice compared with controls (Fig. 1i). Altogether, 
our results show that Nnmt is a novel regulator of hepatic glucose and cholesterol 
metabolism in vivo.
To explore the potential role of NNMT in human physiology we examined the correlation 
between liver NNMT expression and multiple metabolic parameters in a cohort of obese 
non-diabetic individuals (Supplementary Table 2). Liver NNMT correlated positively with 
glucose infusion rate (P = 0.03) suggesting enhanced glucose disposal (Table 1). We found 
significant inverse correlations between liver NNMT expression, total cholesterol (P < 
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0.0001) and low-density lipoprotein (LDL) cholesterol levels (P < 0.0001), fasting TG levels 
(P < 0.03) and cortisol levels (P < 0.045) (Table 1). The most robust correlations were 
observed between NNMT and cholesterol (total and LDL) (Fig. 2a,b). The coefficients of 
determination, R2 = 0.348 for total cholesterol and R2 = 0.41 for LDL cholesterol, suggest 
that variation in human liver NNMT expression can account for as much as 35–40% of the 
variation in the serum cholesterol of our subjects. In addition, liver inflammation decreased 
with increasing NNMT expression (Fig. 2c). These results implicate liver NNMT in human 
physiology.
Sirt1 is required for the metabolic actions of Nnmt
To explore whether Sirt1 is involved in the metabolic effects of Nnmt, we assessed the 
acetylation status of FoxO1, a well-regarded target of Sirt1 and thus used it as readout of 
Sirt1 activity. Acetylation of FoxO1 was significantly higher in primary hepatocytes with 
Nnmt knockdown in vitro compared with controls, indicating decreased Sirt1 activity (Fig. 
3a). The opposite was also true as we found that FoxO1 acetylation was significantly lower 
in primary hepatocytes overexpressing Nnmt in vitro compared with controls (Fig. 3b). The 
livers of mice with Nnmt knockdown had significantly higher FoxO1 acetylation compared 
with control mice (>4-fold), suggesting impaired Sirt1 activity in vivo (Fig. 3c).
To test the causal involvement of Sirt1 in mediating the effects of Nnmt, we treated primary 
hepatocytes with the Sirt1 inhibitors sirtinol and EX-527. G6pc and Pck1 expression was 
significantly lower in inhibitor-treated hepatocytes compared with untreated hepatocytes 
overexpressing Nnmt (Fig. 3d,e). Pretreatment with the specific Sirt1 inhibitor EX-527 
significantly lowered glucose production in inhibitor-treated hepatocytes compared with 
untreated hepatocytes overexpressing Nnmt (Fig. 3f). We also speculated that increasing 
Sirt1 expression should rescue the effects of Nnmt knockdown on the gluconeogenic gene 
expression. As expected, adenoviral overexpression of Sirt1 rescued the suppression of 
G6pc and Pck1 expression caused by Nnmt knockdown, showing that Sirt1 is both necessary 
and sufficient to mediate the effects of Nnmt on gluconeogenesis (Fig. 3g).
Nnmt regulates Sirt1 stability
To investigate how Nnmt affects Sirt1 activity and metabolic pathways, we measured the 
content of Nnmt substrates and products, SAM, SAH, NAM, MNAM and the Sirt1 
substrate, NAD+. SAM/SAH ratio, intracellular NAD+ and NAM content did not change in 
primary hepatocytes with Nnmt knockdown in vitro and in the livers of mice with Nnmt 
knockdown in vivo compared with controls (Supplementary Fig. 3a,b,c). Only the product of 
Nnmt, MNAM showed changes consistent with changes in Nnmt expression. Intracellular 
MNAM content was significantly higher (∼2.5-fold) in primary hepatocytes overexpressing 
Nnmt in vitro compared with controls (Supplementary Fig. 3d). MNAM content was below 
the detection limit in primary hepatocytes with Nnmt knockdown in vitro and was lower 
(30%) in the livers of mice with Nnmt knockdown in vivo compared with controls 
(Supplementary Fig. 3d).
As neither the SAM/SAH ratio nor NAD+ content, previously shown to be higher in 
adipocytes from Nnmt knockdown mice27, were changed in hepatocytes, we considered 
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alternative ways Nnmt might be regulating Sirt1-dependent pathways. In particular, we 
examined whether Nnmt affects Sirt1 itself and noticed that expression of Sirt1 protein was 
significantly higher (>10-fold) in primary hepatocytes overexpressing Nnmt in vitro (Fig. 
4a) and significantly lower (50%) in primary hepatocytes with Nnmt knockdown in vitro 
compared with controls (Fig. 4b). As an additional control, expression of Nampt, the 
enzyme regulating the limiting step in the nicotinamide salvage pathway, was not affected 
by changes in Nnmt expression (Fig. 4a,b). Sirt1 protein was also significantly lower in the 
livers of Nnmt knockdown mice compared with control mice (Fig. 4c). In the same 
experiments, Sirt1 mRNA expression was not changed, suggesting that Nnmt might be 
regulating the stability of Sirt1 protein. We measured Sirt1 half-life in primary hepatocytes 
treated with cyclohexamide, an inhibitor of protein translation. Sirt1 half-life was longer in 
Nnmt overexpressing hepatocytes (>25 h) compared with control (AdGFP) hepatocytes 
(10h) (Fig. 4d). Importantly, in human liver biopsies, SIRT1 protein correlates positively 
with NNMT expression (r = 0.797, n = 12) (Fig. 4e).
Regulation of Sirt1 protein stability is not well understood. Recent studies implicate the 
proteasome in the degradation of Sirt1 through ubiquitin-dependent and independent 
pathways and through caspase-mediated degradation33–35. We treated primary hepatocytes 
with the proteasome inhibitor MG132 for up to 20 h because toxicity ensues at later time. 
Thus expression of Sirt1 protein was modestly higher (∼2-fold) compared to untreated 
hepatocytes and comparable to that seen with Nnmt overexpression over the same time 
course (Supplementary Fig. 4a). In addition, the difference in Sirt1 protein expression 
between control and NNMT overexpressing hepatocytes was much smaller in MG132-
treated cells consistent with the idea that Nnmt inhibits proteasome degradation of Sirt1. We 
treated cells with MG132 to accumulate ubiquitinated proteins and show that Nnmt 
overexpression lowers Sirt1 ubiquitination (Supplementary Fig. 4b) but does not affect 
general proteasome activity (Supplementary Fig. 4c).
MNAM mediates the metabolic function of Nnmt
Since Nnmt is an enzyme, we examined whether its enzymatic activity is required for the 
increased Sirt1 protein expression. To generate enzymatically inactive Nnmt, we modeled 
NAM into the available X-ray structure of mouse Nnmt and selected to independently 
mutate tyrosine 20 (Y20) and alanine 198 (A198) to tryptophan (Supplementary Fig. 
5a)36–38, predicting that increasing the bulkiness of the side chain would disrupt NAM 
binding and thus Nnmt activity. We expressed wild type (wt) Nnmt (Nnmt-wt) and the 
mutants Nnmt-Y20W and Nnmt-A198W in a heterologous cell line and tested the 
immunoprecipitated proteins for their ability to methylate NAM. In contrast to wt Nnmt, 
neither Nnmt mutant was able to methylate NAM in the presence of its co-substrate SAM, 
despite similar amounts of Nnmt protein in the extracts (Supplementary Fig. 5b,c). Next, we 
co-transfected Sirt1 with either the wt or the Nnmt mutants to test their ability to increase 
Sirt1 protein expression and confirmed that Nnmt activity is required for this effect 
(Supplementary Fig. 5d).
These observations led us to test MNAM, the product of Nnmt. Although traditionally 
considered an inactive or toxic metabolite of terminal nicotinamide clearance, recent 
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publications suggest that, at pharmacological doses, MNAM has biological activity and 
affects endothelial cell function39–41. Addition of MNAM to the media of primary 
hepatocytes resulted in 3-fold higher intracellular MNAM content compared with controls 
(Fig. 4f). Similar to Nnmt overexpression, MNAM treated hepatocytes showed a dose-
dependent increase in Sirt1 protein expression compared with controls (Fig. 4g), and in 
G6pc and Pck1 mRNA expression without affecting Sirt1 or Nnmt mRNA expression (Fig. 
4h). Consistent with the higher G6pc and Pck1 expression, MNAM-treated hepatocytes had 
higher glucose production (2-fold) compared with controls and these changes were 
abolished by Sirt1 knockdown (Fig. 4i,j). MNAM-treated cells had lower ubiquitinated Sirt1 
protein without affecting general proteasome activity (Supplementary Fig. 5e,f) and MNAM 
does not directly affect Sirt1 activity in vitro (Supplementary Fig. 5g).
MNAM improves the metabolic profile of HFD-fed mice
Increasing Sirt1 expression improves the metabolic profile of diet-induced obese (DIO) 
mice16,17,42. Since the small metabolite MNAM mediates the metabolic activity of Nnmt, 
we expected that in vivo treatment with MNAM would increase liver Sirt1 protein and 
improve the metabolic profile of mice fed a HFD. To test this idea, we fed several cohorts of 
wt C57BL6/J mice a HFD supplemented with different doses of MNAM (0.3% and 1%) for 
several weeks. MNAM content was 4-fold higher in the livers of MNAM-supplemented 
(HFD1%) compared with control mice (HFD) indicating that it is orally bioavailable 
(Supplementary Fig. 6a). HFD-fed mice gained an additional 7 grams of body weight after 8 
weeks compared with mice fed low-fat control diet (CD) but MNAM supplementation had 
no effect on body weight gain (Supplementary Fig. 6b). Liver Sirt1 protein expression was 
significantly lower (50%) in HFD-fed compared with CD-fed mice (Fig. 5a). MNAM-
supplemented mice had higher liver Sirt1 protein expression compared with mice fed HFD 
alone and beyond the levels seen on CD (Fig. 5a). The mRNA expression of Sirt1 followed 
the opposite pattern from the protein, suggesting that HFD regulates Sirt1 protein stability 
and MNAM reverses this effect (Fig. 5a).
Consistent with higher Sirt1 protein expression, liver FoxO1 acetylation was significantly 
lower in the livers of MNAM-supplemented mice (HFD1%) compared with control mice 
(HFD) (Fig. 5b). MNAM prevented the changes in fasting glucose and insulin caused by 
HFD, however this effect was transient and persisted only for one week (Fig. 5c). More 
sustained effects were seen on lipids and cholesterol. Serum TGs were not affected by HFD 
and MNAM treatment throughout the course of the studies (not shown) but MNAM-treated 
mice (HFD1%) had significantly lower liver TGs (60%) compared with control mice (HFD) 
(Fig. 5d) and the pattern of gene expression suggested that fatty acid synthesis is inhibited 
by MNAM (Supplementary Fig. 6c). Indeed, ex vivo hepatocytes isolated from mice treated 
with MNAM (HFD1%) had significantly lower fatty acid synthesis (58%) compared to 
control hepatocytes (HFD) (Fig. 5d). HFD-fed mice had significantly higher serum 
cholesterol compared to control mice (CD) and MNAM supplementation of HFD prevented 
this increase for several weeks (Fig. 5e), although by 8-weeks the effect was no longer 
apparent (not shown).
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We also analyzed the lipoprotein profile to determine size of the particles carrying 
cholesterol. Plasma from HFD-fed mice had higher cholesterol content in HDL fractions 
(30–40) and in intermediate fractions (20–30) compared with CD-fed mice (Fig. 5f). 
MNAM-treated mice (HFD1%) had lower cholesterol in the intermediate fractions (20–30) 
compared with HFD-fed mice, suggesting a selective effect on the more atherogenic 
lipoprotein particles (Fig. 5f). After 8 weeks on HFD, liver cholesterol was significantly 
lower (75%) in MNAM-treated mice (HFD vs HFD1%) (Fig. 5g). Fecal cholesterol output 
was also lower in MNAM-treated mice compared to HFD alone, suggesting that the lower 
liver cholesterol was due to the decreased synthesis and not increased cholesterol clearance 
(Fig. 5g). As expected, cholesterol synthesis was lower (75%) in hepatocytes isolated from 
MNAM-treated mice (HFD1%) compared with control hepatocytes (HFD) (Fig. 5g).
Gene expression survey of cholesterol metabolic pathways was consistent with the liver 
cholesterol profile. Expression of the master cholesterol regulators Srebf2 and Nr1h3 
(encoding LXRα) and several of their target genes in cholesterol synthesis (Srebf2, Hmgcs1) 
and transport (Ldlr, Abca1, Abcg8) were significantly higher in the livers of HFD-fed 
compared with CD-fed mice and MNAM supplementation of HFD prevented these changes 
in a dose-dependent manner (Supplementary Fig. 6d,e). Consistent with the improved 
metabolic profile of the liver, MNAM-fed mice had significantly lower liver expression of 
the proinflammatory cytokines Tnf and Il6 compared with HFD-fed mice (Supplementary 
Fig. 6f). To test if the metabolic effects of MNAM require Sirt1 activity in vivo, we fed mice 
HFD supplemented with MNAM in combination with the Sirt1 inhibitor EX-527. Sirt1 
inhibition blocked the beneficial effects of MNAM on liver cholesterol and liver TGs. 
Changes in serum cholesterol showed similar trends but did not reach significance (Fig. 5h). 
Our data indicate that pharmacological doses of MNAM improve the metabolic 
dysregulation caused by HFD feeding. A schematic representation of the proposed pathway 
shows NAM increasing Sirt1 activity through NAD+ biosynthesis and Sirt1 protein through 
Nnmt and MNAM (Fig. 5i).
Discussion
Nnmt has recently emerged as a novel metabolic regulator27. Adipose tissue Nnmt 
expression correlates positively with adiposity in mice and antisense oligonucleotide 
knockdown of Nnmt protected against DIO27. In humans, adipose tissue NNMT expression 
and its product MNAM correlate positively with insulin resistance43. The function of Nnmt 
in the liver, a site of major Nnmt expression, is not well investigated. Dietary regulation of 
liver Nnmt expression shows some interesting patterns. Ketogenic diet feeding significantly 
suppresses liver Nnmt expression, which may contribute to the increased serum and liver 
cholesterol in this dietary model44. Of considerable interest is the increased Nnmt 
expression in C57BL6 mice under caloric restriction, as this would promote Sirt1 protein 
stability, which mediates many of the metabolic effects of caloric restriction16. Other strains 
of mice show a much more impressive response. Caloric restriction of the outbred ICR mice 
increases liver Nnmt expression 36.5-fold45. The contribution of Nnmt to the metabolic 
benefits of caloric restriction should be addressed in future experiments. Our data do not 
support the idea that downregulation of Nnmt expression contributes to the pathogenesis of 
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obesity, at least in the models tested, as NNMT expression was either unchanged or even 
increased in the livers of HFD-fed and db/db mice, respectively.
Liver Nnmt is a major variable expression locus in mice46 and it correlates inversely with 
serum cholesterol, TGs and free fatty acid levels among other markers. Remarkably, we 
observed similar associations in a human obese cohort with significant inverse correlation 
between liver NNMT expression and serum total cholesterol, LDL cholesterol, TG levels and 
other parameters. The most significant associations are between NNMT and LDL cholesterol 
accounting for up to 40% of the variation in LDL cholesterol in our cohort and could 
potentially explain a large fraction of the variation in cholesterol in other human populations 
as well. Altogether, associations from mice and humans suggest that increased liver NNMT 
expression correlates with an improved metabolic profile, in contrast to its expression in 
adipose tissue27,43. We speculate that the significant variation in liver NNMT expression 
underlies the natural variation in metabolic traits seen among mice and humans and 
individuals with lower liver NNMT expression could be predisposed to the deleterious 
consequences of nutrient excess.
We tested the causal role of Nnmt in metabolic regulation by adenoviral knockdown and 
overexpression in vitro and in vivo in mice and showed that Nnmt regulates hepatic glucose, 
lipid and cholesterol metabolism. The mechanism of action underlying this regulation by 
Nnmt in the liver is completely different from adipose tissue. Nnmt is not a major 
methyltransferase in the liver and does not change methyl donor balance in hepatocytes in 
contrast to adipocytes and cancer cells27,47. This is not surprising, as liver expresses other 
major methyltransferases, which account for the majority of the methyl donor flux in this 
tissue48. Instead, we found that the metabolic effects of Nnmt are mediated by its product 
MNAM. Both Nnmt and MNAM increase Sirt1 protein expression independent of its 
mRNA levels, while Sirt1 is necessary for the metabolic effects of Nnmt and MNAM. Our 
results are consistent with a large body of literature implicating Sirt1 in the regulation of 
gluconeogenesis and cholesterol synthesis4,6,7,11.
The stability of Sirt1 itself is poorly understood and alternative pathways have been 
proposed34,35,49. Our data suggest that Nnmt and MNAM regulate the ubiquitin-proteasome 
degradation of Sirt1. Whether MNAM binds directly to Sirt1 itself or another protein 
involved in Sirt1 degradation is not known. Very recently, Mdm2 has been proposed as the 
Sirt1 E3-ligase and represents a potential candidate50. MNAM has long been considered an 
inactive metabolite. Recent studies show that it possesses anti-inflammatory and 
antithrombotic activity with incompletely understood mechanism of action, and also 
increases C.elegans life span through mitohormetic effects39,40,51. Our results define a novel 
intracellular mechanism for the metabolic effects of Nnmt through the production of an 
active endogenous metabolite MNAM that could be applicable to other cell types where 
Nnmt is strongly expressed, such as adipose tissue, endothelium, cancer cells, and possibly 
on cells not expressing Nnmt through paracrine effects of secreted MNAM.
We anticipated beneficial effects of dietary MNAM supplementation in mice fed a HFD 
because MNAM increased Sirt1 protein expression in vivo16–18. In line with the known 
metabolic effects of Sirt1, MNAM significantly lowered liver cholesterol and TG levels, 
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while also suppressing fatty acid and cholesterol synthesis and the expression of lipogenic 
and cholesterol synthesis genes. MNAM supplementation also suppressed the expression of 
several target genes of Nr1h3 (encoding Lxrα) and Nr1h4 (encoding Fxr) in cholesterol and 
bile acid transport. It has been previously shown that Sirt1 deacetylates and activates Lxrα 
and Fxr52,53, therefore the reduction in their target genes is likely indirect and secondary to 
the reduced availability of their ligands due to the suppression of cholesterol synthesis.
We also observed systemic effects of MNAM with significant lowering of serum cholesterol 
and changes in lipoprotein profile. Mouse lipoprotein metabolism differs from humans, as 
most of the cholesterol is transported in HDL and not LDL. MNAM supplementation 
produced a selective decrease in larger lipoprotein particles and not HDL, suggesting that 
MNAM or its derivatives could be used to decrease LDL levels in humans. Serum TG levels 
did not change in our experiments. However, it should be noted that HFD and C57BL6 mice 
are not ideal models of triglyceridemia and a TG-lowering effect of MNAM has been 
reported in a rat model in the context of a high fructose diet41.
Methylation of NAM by Nnmt is a major pathway for the clearance of excess vitamin B3 
from the body. Here we ascribe it a novel and unexpected function in Sirt1-dependent 
metabolic regulation. Thus in addition to well-established NAD+ biosynthetic pathways, 
which stimulate Sirt1 activity by increasing NAD+ levels, vitamin B3 clearance pathways 




NAM, cyclohexamide, MG132, 8-Br-cAMP, Percoll and dexamethasone were obtained 
from Sigma-Aldrich (St.Louis, MO). MNAM was from Sigma-Aldrich (St.Louis, MO) and 
TCI America (Portland, OR). Nnmt chicken polyclonal antibody (29–288–23087) was from 
Genway (San Diego, CA). Nnmt rabbit antibody (ARP42281) was from Aviva Systems 
Biology (San Diego, CA). Sirt1 antibody (2028S) was from Cell Signaling (Danvers, MA). 
Actin mouse monoclonal antibody (ab3280) was from Abcam (Cambridge, MA). 
FoxO1antibody (sc-11350) was from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit 
anti Acetyl-lysine antibody (9441S) was from Cell Signaling (Danvers, MA). Secondary 
antibodies goat anti-chicken (703-035–155), donkey anti-Mouse (715-035–150) and donkey 
anti-Rabbit (711-035–152) were from Jackson Immunoresearch (West Grove, PA). Glucose 
was measured with the One Touch Ultra Mini glucose meter (Lifescan).
Mouse purchase
Eight week old C57BL6/J male mice were purchased from Jackson labs (Bar Harbor, ME). 
Mice were group housed with ad libitum access to food except where indicated. Water was 
available at all times. All procedures were approved by the Beth Israel Deaconess Medical 
Center IACUC.
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Primary hepatocyte Isolation and culture
Primary hepatocytes were isolated from 8-week old C5BL6/J male mice by the collagenase 
perfusion method. Hepatocyte preparation media were from Invitrogen (Carlsbad, CA). 
Viable hepatocytes were enriched by Percoll gradient centrifugation. The hepatocytes were 
resuspended in Williams’ E Medium containing 10% FBS and seeded on collagen coated 
plates at a density of 800,000/ml. After a 4-hour attachment period the medium was 
switched to Williams’ E medium without serum containing insulin, transferrin and selenium 
(ITS) from Invitrogen and changed daily.
Adenovirus construction
Nnmt cDNA was cloned from the liver of C57BL6 mice and a Flag epitope was introduced 
to the N-terminus. Nnmt cDNA was cloned into the adenovirus vector pAd/CMV/V5-Dest 
(Invitrogen). ShRNA against Nnmt was obtained from the Broad Institute (Cambridge, MA) 
and cloned into the pAd/PL-Dest (Invitrogen). Control viruses contained either GFP or 
irrelevant shRNA. Adenoviruses were generated by the Harvard Gene Therapy Initiative 
Research Vector Core. The titers of the purified viruses ranged from 5–20 × 1010 pfu/ml.
Adenovirus infection
Primary hepatocytes were infected by overnight exposure to adenovirus (unless otherwise 
indicated) in William’s E medium at MOI 10. For Nnmt overexpression experiments, the 
hepatocytes were typically cultured for 48 hours. For Nnmt knockdown, the hepatocytes 
were typically cultured for 96 hours to allow for the degradation of the endogenous protein. 
For Sirt1 knockdown, hepatocytes were infected with adenovirus (MOI 30) overnight. At 
the same time, the hepatocytes were treated with 0.1 mM MNAM added to the media. After 
48 hours the cells were used for gene expression assay or glucose production experiments. 
For EX-527 treatment, hepatocytes were incubated with 30 µM of EX-527 overnight prior to 
harvest.
Immunoblotting
Hepatocytes or livers were homogenized in RIPA buffer with protease, phosphate inhibitors 
and deacetylase inhibitors and lysed for 30 minutes at 4°C, followed by centrifugation for 15 
minutes. Protein concentration of the supernatant was measured by the Bradford assay (Bio-
Rad). 10 µg of total protein was analyzed by SDS-PAGE (Criterion gels, Bio-Rad) and 
transferred to nitrocellulose for 1 hr at 100V. The membrane was blocked with 5% BSA in 
TBST for 1 hour at room temperature and then incubated with the primary antibody 
overnight at 4°C. The next day, the membrane was washed 3 times with TBST and 
incubated with HRP-conjugated secondary antibody for 45 minutes at room temperature, 
followed by 3 more washes in TBST. Antibody binding was detected using 
chemiluminescence reagents from Pierce (Rockford, IL).
Glucose production
Primary mouse hepatocytes were plated on collagen I-coated 12-well plates (0.4 × 106/well). 
4 hours later, the cells were infected with virus (MOI 10) overnight. For Nnmt over-
expressing cells, media containing virus were washed away and switched to fresh 
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maintenance media in the morning and then switched to William’s E media containing 0.5 
mM cAMP and 0.1 µM dexamethasone at the end of the day. 18 hours later, the media were 
removed and the cells were rinsed with PBS twice. Then, 450 µl of glucose production 
buffer (consisting of glucose-free DMEM pH 7.4 without phenol red, 20 mM sodium 
pyruvate, 2mM L-glutamine and 15 mM Hepes) were added to the cell. 6 hours later, media 
were collected and the amount of glucose in the media was determined by the glucose assay 
kit (Sigma Aldrich). For Nnmt knockdown, cells were cultured for 3 more days after the 
cells were infected with virus. Then the cells were treated with William’s E media 
containing 0.5 mM cAMP and 0.1 mM dexamethasone for 18 hours and subsequently 450 µl 
of glucose production buffer. Media were collected at 6 hours and measured for glucose 
content as described in Nnmt overexpressing cells.
G6pc and Pck1 induction
18 hours before harvest, hepatocytes were washed once with PBS and switched to Williams' 
E medium containing 0.5 mM 8-Br-cAMP and 100 nM dexamethasone. After the treatment, 
hepatocytes were washed once with PBS and harvested for further analysis.
RNA extraction, cDNA synthesis and Quantitative PCR
RNA was extracted according to manufacturers instructions with the RNeasy kit from 
Qiagen (Valencia, CA). cDNA was prepared with the RT-for-PCR kit from Clontech 
(Mountain View, CA) or Quantitect Reverse Transcription kit (Qiagen). QPCR was 
performed with the SybrGreen Master Mix (Applied Biosciences) in a 7900HT cycler 
(Applied Biosciences). Cyclophilin or TBP was used for normalization. Sequences of the 
primers are available upon request.
Adenovirus infection of mice
Eight week old wt C57BL6/J male mice were injected via tail vein with a total viral load of 
3×109 pfu/mouse in 100 µl of sterile PBS/3% glycerol. Mice were randomly allocated with 
respect to the virus. 7–10 days after infection mice were deeply anesthetized by ketamine/
xylazine. Tissues were harvested and rapidly frozen in liquid nitrogen until further 
processing.
Pyruvate tolerance test
Ten days after virus-injection, mice were fasted overnight and injected intraperitoneally with 
pyruvate (2 g/kg body weight). Serum glucose was measured at 0, 15, 30, 60, 90 and 120 
minutes after the injection.
Human subject recruitment
The human subject cohort comprised of 53 morbidly obese subjects (9 men and 44 women) 
at the Endocrinology Service of the Hospital Universitari de Girona Dr. Josep Trueta 
(Girona, Spain). Pre-established inclusion criteria: All subjects were of Caucasian origin. 
The subjects reported a stable body weight three months preceding the study, were free of 
any infections one month before and had no systemic disease. Pre-established exclusion 
criteria: Subjects with liver disease, specifically HCV infection and tumor disease, and 
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subjects with thyroid dysfunction were excluded by biochemical work-up. A small number 
of participants were under hypolipidemic treatment [fibrates (n = 3) and statins (n = 7)]. 
Samples from all the subjects were obtained during elective gastric by-pass surgery. Liver 
samples were collected in RNA later, fragmented and immediately flash-frozen in liquid 
nitrogen before storage at −80°C.
Liver biopsies were analyzed by a single expert pathologist. The liver samples were stained 
with hematoxylin and eosin, Masson’s trichrome and reticulin. Non-alcoholic fatty liver 
disease (NAFLD) scoring system for was used to assess steatosis, hepatocellular ballooning, 
fibrosis and lobular inflammation 54. Lobular inflammation was graded as absent (0 
inflammatory foci in a 200 x field) or present (>1 inflammatory foci in a 200 x field). The 
study has an 80% power to detect significant correlations (Spearman’s coefficient of at least 
0.3) between variables in bilateral tests. The study was also powered to detect a significant 
difference of at least 0.5 SD units between groups. Two subjects with abnormally low total 
and LDL cholesterol levels were excluded from the metabolite correlations. Statistical 
analysis was performed in SPSS v.21. All subjects gave written informed consent, validated 
and approved by the ethical committee of the Hospital Universitari Dr. Josep Trueta (Comitè 
d’Ètica d’Investigació Clínica).
Analytical determinations (Human)
Serum glucose concentrations were measured in duplicate by the glucose oxidase method 
using a Beckman glucose analyser II (Beckman Instruments, Brea, California). Duplicate 
samples were used for serum insulin determination by the immunoradiometric assay 
(Medgenix Diagnostics, Fleunes, Belgium). The coefficients of variation (intra-assay) were 
5.2% at a concentration of 10 mU/l and 3.4% at 130 mU/l. The coefficients of variation 
(inter-assay) were 6.9 and 4.5% at 14 and 89 mU/l, respectively. Total serum cholesterol 
was measured by an enzymatic, colorimetric method through the cholesterol esterase/
cholesterol oxidase/peroxidase reaction (Cobas CHOL2). HDL cholesterol was quantified 
by a homogeneous enzymatic colorimetric assay through the cholesterol esterase/cholesterol 
oxidase/peroxidase reaction (Cobas HDLC3). Total serum TGs were measured by an 
enzymatic, colorimetric method with glycerol phosphate oxidase and peroxidase (Cobas 
TRIGL). LDL cholesterol was calculated using the Friedewald formula. Cortisol was 
etermined by routine laboratory test.
Euglycemic hyperinsulinemic clamp (Human)
Insulin action was determined by the euglycemic hyperinsulinemic clamp. After an 
overnight fast, two catheters were inserted into an antecubital vein, one for each arm, used to 
administer constant infusions of glucose and insulin, and to obtain arterialized venous blood 
samples. A 2-h euglycemic hyperinsulinemic clamp was initiated by a two-step primed 
infusion of insulin (80 mU/m2/min for 5 min, 60 mU/m2/min for 5 min) immediately 
followed by a continuous infusion of insulin at a rate of 40 mU/m2/min (regular insulin 
(Actrapid, Novo Nordisk, NJ)). Glucose infusion began at minute 4 at an initial perfusion 
rate of 2 mg/kg/min being then adjusted to maintain plasma glucose concentration at 4.9–5.5 
mmol/L. Blood samples were collected every 5 minutes for determination of plasma glucose 
and insulin. Insulin sensitivity was assessed as the mean glucose infusion rate during the last 
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40 min. In the stationary equilibrium, the amount of glucose administered (M) equals the 
glucose taken by the body tissues and is a measure of overall insulin sensitivity.
Gene expression analyses (Human)
RNA was prepared from liver biopsies using the RNeasy Lipid Tissue Mini Kit (QIAgen; 
Gaithersburg, MD). The integrity of each RNA sample was evaluated by the Agilent 
Bioanalyzer® (Agilent Technologies; Palo Alto, CA). Total RNA was quantified 
spectrophotometrically (GeneQuant, GE Health Care; Piscataway, NJ) or with the 
bioanalyzer. Three µg of RNA were reverse transcribed to cDNA using the High Capacity 
cDNA Archive Kit (Applied Biosystems; Darmstadt, Germany) according to the 
manufacturer’s protocol.
Gene expression was measured by real time quantitative PCR using the LightCycler® 480 
Real-Time PCR System (Roche Diagnostics; Barcelona, Spain), using TaqMan® technology 
suitable for relative gene expression quantification. The reaction was performed in a final 
volume of 12 µl following the manufacturer’s protocol. The cycle program consisted of an 
initial denaturation for 10 min at 95°C followed by 40 cycles of 15 s denaturing phase at 
92°C, 1 min annealing and extension phase at 60°C. Cyclophilin A. The pre-validated 
TaqMan® primer/probe set for cyclophilin was used as the endogenous control for the target 
genes in each reaction: cyclophilin A (PPIA; Hs99999904_m1, RefSeq. NM_021130.3). Pre-
validated SybrGreen primers for human Nnmt were purchased from Roche Diagnostics 
(Barcelona, Spain). Primers sequences are as follows: NNMT forward: 5’-
AGCTGGAGAAGTGGCTGAAG-3’ and NNMT reverse: 5’-
TGGACCCTTGACTCTGTTCC-3’.
The Second Derivative Maximum Method was used for the determination of the crossing 
points (Cp). A Cp value was obtained for each amplification curve and ΔCp value was first 
calculated by subtracting the Cp value for human PPIA cDNA from the Cp value for each 
sample and transcript. Fold changes compared with the endogenous control were then 
determined by calculating 2−ΔCp, so gene expression results are expressed in all cases as 
expression ratio relative to PPIA gene expression, according to manufacturers’ guidelines.
FoxO1 acetylation
Hepatocytes (8×105) were plated into 6-well plates and infected with a control or Nnmt 
overexpressing adenovirus overnight. Next day the cells were infected again with the virus 
expressing FoxO1. 24 hours later, the cells were harvested in 200 µl high salt lysis buffer 
(1% Triton, 500 mM NaCl, 50 mM Tris-HCl pH 7.4 and inhibitors). After 30min incubation 
on ice, lysates were centrifuged at full speed for 30 minutes at 4°C. The supernatant was 
diluted with 2 volumes of dilution buffer (50 mM Tris-HCl pH7.4 with inhibitors) to bring 
down the concentration of Triton and salt. 250 µg of total protein from each sample was 
incubated with 2 µg of FoxO1 primary antibody overnight at 4°C. The next day 40 µl of 
protein A/G slurry was added for another 4 hours. The beads were then washed 3 times with 
wash buffer (0.3% Triton, 150 mM NaCl, 50 mM Tris-HCl) After the final wash, the beads 
were eluted with 40 µl l 2X sample buffer and boiled at 95 degree for 5 minutes. 20 µl of the 
eluate was resolved by SDS-PAGE gel and probed with the indicated antibodies. For liver 
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endogenous FoxO1 acetylation assay, liver pieces were lysed and immunoprecipitated as 
described above. Briefly, 4 mg of total proteins were incubated with 2 µg of primary 
antibody overnight and then 40 µl of protein A/G slurry for 4 hours. The beads were then 
washed with wash buffer and eluted with 50µ 2X sample buffer. 20 µl of the eluate was 
loaded for western blotting.
HPLC methods
Hepatocytes infected with adenoviruses as described and treated with 1 mM of nicotinamide 
for 24 hours. Media were collected, centrifuged for 5 min and injected into HPLC for NAM 
and MNAM analysis. Hepatocytes were harvested in ice-cold 80% methanol and incubated 
at –80°C for 15 min. After centrifugation, the supernatant was dried under vacuum, 
resuspended in dH2O and analyzed by HPLC. 6-methylnicotinamide was included as an 
internal standard to account for sample loss during extraction. The metabolites were 
separated on Atlantis T3 column (4.6 mm id, 100 mm length) using the Breeze System 
(Waters, MA) protected by a 20 mm guard column. Metabolites were eluted isocratically in 
20 mM KH2PO4 pH 3, 5% methanol, 2 mM sodium heptanesulfonic acid at 0.7 ml/min flow 
rate. NAM, MNAM were detected by UV absorption at 260 nm and identified by its 
retention time compared to standards.
Sirt1 degradation
Primary hepatocytes were infected with a control or Nnmt overexpressing adenovirus 
overnight and cultured for additional 24 hours. The cells were then treated with 10 µg/ml 
cyclohexamide and harvested at different time points in RIPA buffer with inhibitors. 10 µg 
of total protein from each sample were resolved by SDS-PAGE gel and probed with the 
indicated antibodies.
HEK293T transfection
HEK293T were originally purchased from ATCC and maintained in DMEM-HG containing 
10% FBS. Cells were transfected with 0.05 µg plasmid encoding HA-Sirt1 along with 0.5 µg 
plasmid encoding either GFP, Flag-Nnmt-wt, Flag-Nnmt-Y20W or Flag-Nnmt-A198W with 
Lipofectamine 2000 (Invitrogen). 48 hours after the transfection, cells were rinsed with PBS 
and harvested in RIPA buffer. 10 µg of total protein from each sample was resolved by SDS-
PAGE gel and probed with the indicated antibodies.
Proteasome assay
HEK293T cells were lysed on ice for 30 minutes in the lysis buffer provided in the 20S 
Proteasome assay kit (Cayman Chemicals, Ann Arbor, MI) and spun for 30 minutes. The 
supernatant was transferred to a new tube and incubated with increasing concentrations of 
MNAM for 15 min at room temperature. The proteasome activity of the supernatant was 
measured following manufacturer’s instructions. The proteasome inhibitor MG132 was used 
as a positive control.
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MNAM treatment
Primary hepatocytes were plated as described. After a 5 hour attachment period, hepatocytes 
were treated with different concentrations of MNAM. After 24 hours, fresh media were 
added (containing NAM) and the incubation continued for another 18 hours before 
harvesting in RIPA buffer. 10 µg of total protein from each sample were resolved by SDS-
PAGE gel and probed with the indicated antibodies.
Sirt1 activity assay
Direct effect of MNAM on Sirt1 activity was measured by the Sirt1 Direct Fluorescent 
Screening Assay Kit (Cayman Chemicals, An Arbor, MI) following manufacturer’s 
recommendations.
HFD experiments
7–8 week old wt C57BL6/J male mice were purchased from Jackson labs. After one-week 
acclimatization, mice were fed HFD-supplemented with MNAM. Individual mice were 
randomly allocated to each experimental group. The only criterion was a matched group 
mean weight. Mice were group-housed with food and water available ad libitum. Irradiated 
HFD (RD12451) and control diet (RD12450K) were purchased from Research Diets (New 
Brunswick, NJ). Diet was grounded in a blender and powdered MNAM was mixed with the 
diet to 0.3% v/v (HFD0.3%) and 1% v/v (HFD1%). For EX-527 feeding experiment, mice 
were fed with 0.01% EX-527 (approximately 10 mg/kg/day) mixed with HFD1%. Fresh diet 
was prepared weekly. At the end of the study mice were fasted for 6 hours, anesthetized by 
ketamine and xylazine and sacrificed by transcardial puncture. Tissues were dissected and 
frozen in liquid nitrogen until further processing.
Cholesterol and fatty acid synthesis
Mice were fed with HFD or HFD1% MNAM for two weeks. Primary hepatocytes from 
these mice were plated in collagen I coated 12-well plates (0.4 × 106/well). After 4 h 
attachment period, hepatocytes were incubated with maintenance media containing 0.2 
mCi/ml [3]H2O. 18 hours later, media were removed, the cells harvested in 0.8 ml of 8N
KOH and transferred to screw-cap tubes. An equal volume of ethanol was added and the 
tubes were heated at 90°C for 2 h with vortexing every 15 minutes. The mixture was 
transferred into 10 ml plastic tubes and nonsaponifiable lipids (cholesterol) were extracted 
two times with 2 ml of petroleum ether. Aliquots of the pooled extract were dried under the 
chemical hood. The 3H radioactivity was determined by scintillation counting and used to 
calculate the rate of cholesterol synthesis. The aqueous phase was acidified with 1 volume of 
6 N HCl and saponifiable lipids were extracted two times with 2 ml of petroleum ether. 
The 3H radioactivity was determined by scintillation counting and used to calculate the rate 
of fatty acid synthesis.
Fecal lipid extraction
One gram of feces from each group of mice was pulverized and transferred to 15ml tube 
containing 2.5 ml water and incubated at 4°C overnight. 5ml Folch reagent (chloroform: 
methanol 2:1) was added to each tube and the contents were vortexed, followed by addition 
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of 1 ml of 0.05% H2SO4 and vortexed again. After 30 minutes incubation at room 
temperature, the tubes were centrifuged for 5 minutes at 2000 rpm. The chloroform phase 
(lower phase) was transferred into a glass tube. The samples were extracted again with 5ml 
Folch reagent and the chloroform phases were pooled. The chloroform extract was vacuum 
dried and dissolved in butanol: Triton X-100: methanol (0.6:0.267:0.133). Cholesterol was 
measured with the enzymatic assay from Stanbio (Boerne, Texas).
Statistics
Typically, 8 mice were randomly allocated to each experimental group. The only criterion 
was a matched group mean weight. Based on our experience, we can detect a 50% 
difference in mean expression of multiple genes using this group size. Exclusion criteria for 
mouse studies were weight loss in excess of 20%, grossly abnormal organ morphology. 
Investigators were not blinded with respect to the experimental groups during animal 
studies. Statistical differences were evaluated in JMP Pro v.10 (SAS). Data are presented as 
mean and standard error (s.e.m.). Pairwise differences we tested by Student’s t-test. Multiple 
comparisons were tested by one-way ANOVA followed by posthoc Dunnett’s with control. 
Some data were log transformed to satisfy normal distribution and equal variance between 
cohorts. Significance was set at P < 0.05. Statistical outliers were identified in JMP Pro and 
excluded from the data.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Nnmt regulates gluconeogenesis and cholesterol metabolism
(a) Nnmt protein expression in control (shcontrol) and Nnmt knockdown (shNnmt)
hepatocytes. (b) Hepatocyte glucose output and mRNA expression of G6pc, Pck1 and Sirt1
in control (shcontrol) and Nnmt knockdown (shNnmt) hepatocytes (representative of 3
independent experiments performed in triplicates). (c) Nnmt protein expression in control
(AdGFP) and Nnmt overexpressing (AdNnmt) hepatocytes. (d) Hepatocyte glucose output
and mRNA expression of G6pc, Pck1 and Sirt1 in control (AdGFP) and Nnmt
overexpressing (AdNnmt) hepatocytes (representative of >3 independent experiments
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performed in triplicates). (e) Overnight fasting blood glucose and insulin in mice with Nnmt 
knockdown (shcontrol n = 8, shNnmt n = 8). (f) Pyruvate tolerance test in mice with Nnmt 
knockdown (shcontrol n = 7, shNnmt n = 5). AUC = area under the curve. (g) Expression of 
gluconeogenic genes in the liver of Nnmt knockdown mice (shcontrol n = 8, shNnmt n = 8). 
(h) Serum and liver cholesterol in ad libitum fed Nnmt knockdown mice (shcontrol n = 8,
shNnmt n = 7). (i) Expression of genes in cholesterol metabolism in Nnmt knockdown mice
(shcontrol n = 8, shNnmt n = 7). Data are presented as mean ± s.e.m. Statistical significance
was tested by unpaired Student’s t-test, *P < 0.05).
Hong et al. Page 21
Figure 2. Human liver NNMT expression correlates with serum cholesterol and liver 
inflammation
(a) Negative correlation between human liver NNMT expression and total cholesterol (n =
41, r = – 0.59, P < 0.0001). Subjects on hypolipidemic drugs (n = 10) were excluded from
the correlation. (b) Negative correlation between human liver NNMT expression and LDL
cholesterol (n = 41, r = –0.64, P < 0.0001). Subjects on hypolipidemic drugs (n = 10) were
excluded from the correlation. (c) Liver NNMT expression according to liver lobular activity
(index of inflammation) (n = 53, *P = 0.0367). RU = relative units.
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Figure 3. Sirt1 is necessary and sufficient for the metabolic effects of Nnmt
(a) Immunobloting of acetylated, total FoxO1 and their ratio in control and Nnmt
knockdown primary hepatocytes (triplicate determination). (b) Immunobloting of acetylated,
total FoxO1 and their ratio in control and Nnmt overexpressing primary hepatocytes
(triplicate determination). (c) Immunoblotting of acetylated and total FoxO1 and their ratio
in the livers of control and Nnmt knockdown mice (shcontrol n = 6, shNnmt n = 7). (d)
Expression of G6pc and Pck1 in control and Nnmt overexpressing primary hepatocytes
treated with the Sirt1 inhibitor sirtinol (representative of 2 independent experiments
Hong et al. Page 23
performed in triplicates). (e) Expression of G6pc and Pck1 in control and Nnmt 
overexpressing primary hepatocytes treated with the Sirt1 inhibitor Ex-527 (performed in 
triplicates). (f) Effect of EX-527 on glucose production in control and Nnmt overexpressing 
primary hepatocytes (triplicate determination). (g) Expression of G6pc and Pck1 in control 
and Nnmt knockdown primary hepatocytes with Sirt1 overexpression (AdSirt1) (triplicate 
determination). Data are presented as mean ± s.e.m. Statistical significance was tested by 
unpaired Student’s t-test, *P < 0.05).
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Figure 4. Nnmt regulates Sirt1 protein stability through its product MNAM
(a) Sirt1 protein and mRNA expression in control and Nnmt overexpressing primary
hepatocytes (representative of 3 independent experiments performed in triplicates). (b) Sirt1
protein and mRNA expression in control and Nnmt knockdown primary hepatocytes
(representative of 3 independent experiments performed in triplicates). (c) Sirt1 protein and
mRNA expression in livers of control and Nnmt knockdown mice (shcontrol n = 8, shNnmt
n = 8). (d) Time course of Sirt1 protein degradation in cyclohexamide-treated control and
Nnmt overexpressing hepatocytes (triplicate determination). (e) Correlation between Nnmt
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mRNA and Sirt1 protein expression from human liver biopsies (n = 12, P = 0.797). (f) 
Supplementation of media with 0.1 mM MNAM increases intracellular MNAM 
concentration (triplicate determination). (g) Dose-dependent effect of MNAM (0–1 mM) on 
Sirt1 protein expression in primary hepatocytes (representative of 2 independent 
experiments). (h) Dose-dependent effect of MNAM (0–0.3 mM) on G6pc ,Pck1, Sirt1 and 
Nnmt expression in primary hepatocytes (representative of 3 independent experiments 
performed in triplicates). (i) Glucose production in primary hepatocytes supplemented with 
MNAM and infected with either control or Sirt1 knockdown adenovirus (triplicate 
determination). (j) G6pc and Pck1 expression in primary hepatocytes supplemented with 
MNAM and infected with either control or Sirt1 knockdown adenovirus (triplicate 
determination). Data are presented as mean ± s.e.m. Statistical significance was tested by 
unpaired Student’s t-test. *P < 0.05. RU = relative units.
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Figure 5. MNAM improves cholesterol and lipid homeostasis in DIO mice
(a) Liver Sirt1, Actin and Sirt1 mRNA from CD, HFD, HFD0.3% and HFD1% fed mice (b)
Liver acetylated and total FoxO1 from HFD and HFD1% fed mice. (c) Blood glucose (4 h
fast), insulin, and quantitative insulin sensitivity index (QUICKI) of mice fed CD, HFD,
HFD0.3% and HFD1%. (d) Liver TGs content of mice fed CD, HFD, HFD0.3%, HFD1% (n
= 5/group) and fatty acid synthesis in primary hepatocytes from mice fed HFD and HFD1%
(n = 6/group, representative of 2 independent experiments). (e) Serum cholesterol (4 h fast)
on days 8, 15 and 32 from mice fed CD, HFD, HFD0.3% and HFD1%. (f) Cholesterol
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content of lipoprotein fractions from mice fed CD, HFD and HFD1%. (g) Liver and fecal 
cholesterol of mice fed CD, HFD, HFD0.3% and HFD1%. Cholesterol synthesis in primary 
hepatocytes from mice fed HFD and HFD1% (n = 6/group, representative of 3 independent 
experiments). (h) Effect of pharmacological Sirt1 inhibition on serum and liver cholesterol 
and liver TGs levels in mice fed a HFD, HFD1%, HFD1%+EX (n = 5/group). (i) Schematic 
representation of the proposed pathway. One-way ANOVA followed by posthoc Dunnett’s 
with control set to HFD: a,c,d,e,g and h. Unpaired t-test: b,d (right panel), g (right panel); n 
= 7 for CD, n = 8 for HFD, HFD0.3%, HFD1% in a,b,c,e,g (left panel); f pooled sample 
from 8 mice/group; g (middle panel) technical triplicate of pooled samples. Data are 
presented as mean ± s.e.m, *P < 0.05.
Hong et al. Page 28
Hong et al. Page 29
Table 1
Correlation among liver NNMT gene expression and selected metabolic parameters.
n = 51 r P
Age (years) – 0.21 0.15
BMI (kg/m2) – 0.08 0.5
Fasting glucose (mg/dl) 0.18 0.25
Total cholesterol (mg/dl) – 0.54 <0.0001
HDL cholesterol (mg/dl) 0.21 0.15
LDL cholesterol (mg/dl) – 0.57 <0.0001
Fasting triglycerides (mg/dl) – 0.31 0.03
Glucose infusion rate (mg/kg/min) 0.32 0.03
Cortisol (µg/dl) – 0.29 0.045
Pearson’s correlation coefficient (r) and P values for associations between liver NNMT expression and selected metabolic parameters in the 
subjects (n = 51). The significant associations persisted after excluding subjects taking hypolipidemic drugs (n = 10).
